ABBOTT LABS' SHARES UP DESPITE PROFIT DIP
Shares of Abbott Laboratories rose after the pharmaceutical and medical products
maker posted solid sales gains for the third quarter even though its profit
slid 15 percent on costs related to a revamping of its manufacturing operations.
Abbott officials also expressed confidence that a bevy of experimental therapies
in its product pipeline could ease the sting of a recent setback for prostate
cancer drug Xinlay.